24. Zeng, F., Patel, B., Andrews, L., Frech-Tamas, F. and Rudolph, A. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin 2010; 26; 2877–87.(47)
25. Sherrill, B., Halpern, M., Khan, S., Zhang, J. and Panjabi, S. Single-pill vs free-equivalent combination therapies for hypertension: a metaanalysis of health care costs and adherence. J Clin Hypertens 2011; 13; 898–909. (48
26. Elijovich, F. and Laffer, C. A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis 2009; 3; 231–40.(49
27. Gradman, A., Parise, H., Lafeuille, M., Falvey, H., Lefebvre, P. Duh, M. Impact of initial antihypertensive treatment with a single-pill combination on blood pressure (BP) goal attainment: a matched cohort study [abstract]. J Clin Hypertens 2011; 13(Suppl. 1); A128.(50
28. Bangalore, S., Kamalakkannan, G., Parkar, S. and Messerli, F. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120; 713–9. (51
29. Pfeffer, M. A., McMurray, J., Leizorovicz, A., Maggioni, A. P., Rouleau, J. L., Van de Werf, F. Califf, R.. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. American heart journal 2000; 140; (5); 727-50.
30. Anand, I. S., Fisher, L. D., Chiang, Y. T., Latini, R., Masson, S., Maggioni, A. P.Cohn, J. N. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107; (9); 1278-83.
31. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349; ( 9054); 747–52.
32. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial–the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355; (9215) ; 1582–7.
33. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, Vol 2003; 362; (9386); 772–6.
34. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362; (9386); 767–71.
35. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358; (15) ;1547–59.
36. Cowan, B. R., Young, A. A., Anderson, C., Doughty, R. N., Krittayaphong, R., Lonn, E. Jennings, G. L. The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics. (TRANSCEND) Clinical research in cardiology,Vol. 98, No. 7, 2009, pp. 421-433.
37. Dragomir, A., Cote, R., Roy, L., Blais, L., Lalonde, L., Berard, A. et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 2010; 48; 418–25.
38. Go, A., Mozaffarian, D., Roger, V., Benjamin, E., Berry, J., Borden, W. et al. Heart disease and stroke statistics – 2013 update – a report from the American Heart Association. Circulation 2013; 127; 143–52.
39. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med2003; 349; ( 20); 1893–906.
40. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351; ( 30): 2058–68.
41. Maione, A., Nicolucci, A., Craig, J. C., Tognoni, G., Moschetta, A., Palasciano, G. Strippoli, G. F. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial. Journal of nephrology 2007; 20; ( 6) ; 646.
42. Krum, H., Massie, B., Abraham, W. T., Dickstein, K., Kober, L., McMurray, J. J. Rogers, A.. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. European journal of heart failure 2011; 3; (1) ; 107-114.
43. Messerli FH, Bangalore S: ALTITUDE trial and dual RAS blockade: the alluring but soft science of the surrogate end point. Am J Med, 2013; 126; ( 3) ; e1-e3.
44. CHEP: [Internet]Canadian recommendations for the management of hypertension.[Último accceso 23 diciembre 2013] 2012. Disponible en: http://toolkit.cfpc.ca/en/files/2012_CHEPRecsBooklet_EN_HCP1030.pdf
45. Wong J: Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed. Diab Vasc Dis Res 2013; 10; ( 3) ; 193–201.
46. Veglio F, Puglisi E, Milan A, Mulatero P: Combinations of renin-angiotensin-aldosterone system antagonists: true advantages? Curr Pharm Des2012; 18; (7) ; 952–7.
47. UK Medicines Information:[Internet] What is the rationale and evidence for combining angiotensin converting enzyme inhibitors with angiotensin II receptor blockers in renal disease?. [Último acceso 23 diciembre 2013]NHS 2012 January 7;Disponible en: https://www.evidence.nhs.uk/
48. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH: Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013; 346; 360.
49. EMA:[Internet] “Review started of combined use of renin-angiotensin system (RAS)-acting agents”.[Último acceso 23 diciembre 2013 ] 2013. Disponible en. http://www.emea.europa.eu/docs/en_GB/document_library/Referrals_document/Renin-angiotensin_system_(RAS)- acting_agents/Procedure_started/WC500143500.pdf
50. Mallat SG: What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? Cardiovasc Diabetol 2012; 11; 32
51. Panjabi, S., Lacey, M., Bancroft, T. and Cao, F. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens 2013; 7; 46–60.
52. Thom S, Poulter N, Field J. UMPIRE Collaborative Group. Effects of a fixed-dose combination on medication adherence and risk factors in patients with or at risk of CVD: The UMPIRE randomized clinical trial. JAMA 2013; 310; 918-29.
53. Gaziano JM. Progress with the polypill? JAMA 2012; 310; 910-11.